News | Blue Earth Diagnostics

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2022

NEWS FROM

01, October, 2024

For U.S audiences only. Results of POSLUMA® (Flotufolastat F 18) Performance in Recurrent Prostate Cancer After Radical Prostatectomy at Low Prostate Specific Antigen (PSA) Levels Presented at ASTRO

24, September, 2024

This press release is for U.S. audiences only. Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

30, July, 2024

This press release is for U.S. audiences only. Blue Earth Diagnostics, a Bracco Company, Announces Results Evaluating Diagnostic Performance of POSLUMA® (Flotufolastat F 18) and Clinical Trial Enrollment in African American Men with Prostate Cancer

15, July, 2024

This press release is for U.S. audiences only. Blue Earth Diagnostics, a Bracco Company, Lauds CMS Proposal to Support Patient Access Through Improved Payment for Specialized Diagnostic Radiopharmaceuticals

08, July, 2024

Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer to Lead Company’s Next Phase of Business Growth

10, June, 2024

This press release is for U.S. audiences only. Blue Earth Diagnostics Highlights Results of Studies Evaluating Impact of Urinary Activity on Image Interpretation and Performance of POSLUMA® (Flotufolastat F 18) and 18F-Flotufolastat PET in Prostate Cancer

29, May, 2024

This press release is for U.S. audiences only. Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18), Axumin® (Fluciclovine F 18) and Investigational 18F-Flotufolastat/18F-rhPSMA-7 at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

08, May, 2024

This press release is for U.S. audiences only. Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA® (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development

25, January, 2024

This press release is for US audiences only. Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA® (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU

16, January, 2024

This press release is for U.S. audiences only. Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming 2024 ASCO Genitourinary Cancers Symposium (ASCO GU)

NEWS FROM

04, December, 2023

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors

28, November, 2023

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Publication of Post-hoc Analysis Evaluating Impact of Urinary Activity on Image Interpretation of POSLUMA® (Flotufolastat F 18) PET in Prostate Cancer.

19, October, 2023

Blue Earth Diagnostics Ltd Collaborates with Sinotau Pharmaceutical Group to Bring Prostate Cancer PET Diagnostic Imaging Agent, Flotufolastat (18F) Injection, to China

03, October, 2023

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Additional Results of POSLUMA® (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

02, October, 2023

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Data on POSLUMA® (Flotufolastat F 18) in Patients with Suspected Biochemical Recurrence of Prostate Cancer and Low-Very Low Prostate Specific Antigen (PSA) Levels Presented at ASTRO

27, September, 2023

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

26, September, 2023

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces CMS Transitional Pass-Through Payment Reimbursement Code for POSLUMA® (Flotufolastat F 18) Injection, Effective October 1, 2023

25, July, 2023

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Addition of POSLUMA® (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer

27, June, 2023

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Reader Reproducibility Results from Phase 3 LIGHTHOUSE Trial of POSLUMA® (Flotufolastat F18) Injection in Newly Diagnosed Prostate Cancer

26, June, 2023

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Results of Post-hoc Analysis Assessing Impact of Urinary Activity on Interpretation of POSLUMA® (Flotufolastat F 18) Injection PET/CT in Prostate Cancer

21, June, 2023

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics and PETNET Solutions Inc, A Siemens Healthineers Company, Announce U.S. Commercial Availability of POSLUMA® (Flotufolastat F 18) Injection for PET Imaging of Prostate Cancer

20, June, 2023

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights POSLUMA® (Flotufolastat F 18) Injection and Investigational 18F-Flotufolastat Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

30, May, 2023

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

29, April, 2023

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer − Results at the American Urological Association’s 2023 Annual Meeting (AUA2023)

16, February, 2023

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Additional Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

09, February, 2023

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study of 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

NEWS FROM

01, December, 2022

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

22, November, 2022

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) at Upcoming RSNA® 2022 Annual Meeting

21, November, 2022

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights Upcoming Presentation of Results from Phase 3 LIGHTHOUSE Study of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

24, October, 2022

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

19, October, 2022

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine (18F)) and Investigational 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer at Upcoming ASTRO Annual Meeting

18, October, 2022

Blue Earth Diagnostics Announces Data-sharing Agreement with Siemens Healthineers and the University Hospital of Technical University of Munich (TUM) for 18F-rhPSMA-7.3, to support AI-based Algorithms Development

19, July, 2022

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Independent Clinical Studies Published Regarding Performance of Axumin® (Fluciclovine F 18) PET Imaging in Patients with Recurrent Prostate Cancer Undergoing Androgen Deprivation Therapy (ADT)

15, June, 2022

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Reader Reproducibility Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

09, June, 2022

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights Presentations on Investigational rhPSMA Radiopharmaceuticals and 18F-Fluciclovine at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

08, June, 2022

Blue Earth Diagnostics Completes Patient Accrual in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

13, May, 2022

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

05, May, 2022

THIS PRESS RELEASE IS FOR U.S. AUDIENCES ONLY. Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer

28, February, 2022

Blue Earth Diagnostics Appoints Dr. David E. Gauden as Chief Executive Officer and Dr. Eugene J. Teoh as Chief Medical Officer

15, February, 2022

Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of 18F-rhPSMA-7.3, an Investigational PET Imaging Agent, in Biochemical Recurrence of Prostate Cancer

01, February, 2022

Blue Earth Diagnostics Highlights Upcoming Presentation of Key Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18F‐rhPSMA‐7.3 in Biochemically Recurrent Prostate Cancer

NEWS FROM 2021

30, November, 2021

Blue Earth Diagnostics Highlights Axumin® (Fluciclovine F18) Presentation at Upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO)

19, October, 2021

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and ¹⁸F-Fluciclovine at Upcoming ASTRO Annual Meeting

27, September, 2021

Blue Earth Diagnostics Announces Results of an Analysis of the Impact of Axumin® (Fluciclovine F 18) PET/CT Imaging on Androgen Deprivation Therapy (ADT) Planning in Recurrent Prostate Cancer

15, September, 2021

Blue Earth Diagnostics Supports Timely Consideration and Passage of the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 by U.S. Congress.

08, September, 2021

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) at Upcoming American Urological Association’s 2021 Annual Meeting

10, August, 2021

Blue Earth Diagnostics Announces Upcoming ¹⁸F-Fluciclovine Presentations at 2021 Society of Neuro-Oncology (SNO) Conference on Brain Metastases

08, June, 2021

Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

02, June, 2021

Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) Presentations at Upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

25, May, 2021

The Lancet Publishes Results of Axumin® (Fluciclovine F 18) PET Imaging Study Demonstrating Improved Patient Outcomes in Patients with Recurrent Prostate Cancer

08, February, 2021

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) at Upcoming 2021 ASCO Genitourinary Cancers Symposium (ASCO GU)

12, January, 2021

Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

05, January, 2021

Blue Earth Diagnostics Acquires Exclusive, Worldwide Rights to Therapeutic Applications of Scintomics’ Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) Technology for Prostate Cancer

NEWS FROM 2020

24, November, 2020

Blue Earth Diagnostics Announces First Patient Doses of PET Imaging Agent rhPSMA-7.3 (18F) in Collaboration with Nucleis Radiopharmaceuticals in Liege, Belgium

20, October, 2020

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and 18F-Fluciclovine at Upcoming ASTRO Annual Meeting

01, July, 2020

Blue Earth Diagnostics Announces Dosing of Initial Patients in Phase 3 SPOTLIGHT Clinical Trial of Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Biochemically Recurrent Prostate Cancer

16, June, 2020

Blue Earth Diagnostics and PETNET Solutions Announce New Commercial Supply Agreement for Axumin® (Fluciclovine F 18) and Investigational rhPSMA-7.3 (18F) Prostate Cancer Imaging Agent

18, May, 2020

Blue Earth Diagnostics Announces Results from Early Clinical Experience with Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Men with Intermediate and High-risk Prostate Cancer

01, May, 2020

Blue Earth Diagnostics CEO Jonathan Allis Appointed Chair of UK Rapid Testing Consortium (UK-RTC) for COVID-19 by UK Department of Health and Social Care

17, March, 2020

Blue Earth Diagnostics Announces Dosing of First Patient in Phase 3 LIGHTHOUSE Clinical Trial of Targeted PET Imaging Agent rhPSMA-7.3 (18F) in Newly Diagnosed Prostate Cancer

11, February, 2020

Blue Earth Diagnostics Announces Upcoming Presentations from FALCON Study of Axumin® (Fluciclovine F18) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer

NEWS FROM 2019

16, September, 2019

Results from Blue Earth Diagnostics’ FALCON Trial Show 64% of Patients with Suspected Recurrent Prostate Cancer Had Change in Management Following Axumin® (Fluciclovine F 18) PET/CT Scan

10, September, 2019

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18), 18F-Fluciclovine and 18F-rhPSMA at Upcoming ASTRO Annual Meeting

01, August, 2019

Bracco Imaging announces completion of acquisition of Blue Earth Diagnostics

27, June, 2019

Blue Earth Diagnostics Announces Highlights of Technical University of Munich Presentations on Initial Clinical Experience with 18F-rhPSMA-7 PET Imaging in High Risk Primary and Biochemical Recurrent Prostate Cancer

26, June, 2019

Blue Earth Diagnostics to be Acquired by Global Leader Bracco Imaging

26, June, 2019

Blue Earth Diagnostics Announces Results from Investigational Clinical Study of Safety and Effectiveness of 18F-Fluciclovine PET Imaging in Adult Glioma

12, June, 2019

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18), 18F-Fluciclovine and 18F-rhPSMA at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

09, May, 2019

Blue Earth Diagnostics continues to expand access to Axumin® (fluciclovine (18F)) in Europe

06, May, 2019

Blue Earth Diagnostics Announces Results of Additional Analyses from LOCATE Trial Evaluating Change in Recurrent Prostate Cancer Management Following Axumin® (Fluciclovine F 18) PET/CT Imaging

06, May, 2019

Blue Earth Diagnostics Announces Results from Initial Clinical Experience of 18F-rhPSMA-7 PET Imaging in High-risk Primary and Biochemical Recurrent Prostate Cancer by Technical University of Munich

24, April, 2019

Blue Earth Diagnostics Announces Presentations on Axumin® (Fluciclovine F 18), 18F-Fluciclovine and 18F-rhPSMA at Upcoming American Urological Association’s 2019 Annual Meeting

16, April, 2019

Blue Earth Diagnostics Announces Addition of Axumin® (fluciclovine (18F)) to EAU Guidelines for imaging in patients with biochemical recurrence in Prostate Cancer

06, March, 2019

Blue Earth Diagnostics celebrates five year anniversary

12, February, 2019

First production and administration of Axumin® (fluciclovine (18F)) in Italy.

06, February, 2019

Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) LOCATE Study Presentation at Upcoming ASCO 2019 Genitourinary Cancers Symposium on Impact on Clinical Management of Recurrent Prostate Cancer

NEWS FROM 2018

12, December, 2018

First production and administration of Axumin® (fluciclovine (18F)) in France.

10, December, 2018

Blue Earth Diagnostics Announces U.S. Food and Drug Administration (FDA) Filing Acceptance of Supplemental New Drug Application (sNDA) for 18F-fluciclovine PET Imaging in Glioma

19, November, 2018

Blue Earth Diagnostics Announces Results of Investigational Phase 3 Blinded Image Evaluation Study of 18F-Fluciclovine PET Imaging in Glioma

14, November, 2018

Blue Earth Diagnostics Announces 18F-Fluciclovine Research Presentation at Upcoming Society for Neuro-Oncology (SNO) Annual Scientific Meeting

17, October, 2018

Blue Earth Diagnostics Announces Fluciclovine F 18 Research Presentations at Upcoming ASTRO Annual Meeting

12, October, 2018

Blue Earth Diagnostics wins prestigious “Best Emerging Biotech” award

02, October, 2018

Axumin® (fluciclovine (18F)) receives positive recommendation from Transparency Committee of the French HAS, for use in PET imaging of suspected recurrent prostate cancer

11, September, 2018

The Journal of Urology Publishes Results from Blue Earth Diagnostics’ LOCATE Trial of Role of 18F Fluciclovine PET/CT Imaging in the Management of Men with Recurrent Prostate Cancer

09, August, 2018

Blue Earth Diagnostics shortlisted for prestigious “Best Emerging Biotech Company” award

25, June, 2018

Blue Earth Diagnostics appoints IASON Sp. z o.o. to manufacture and distribute Axumin® (fluciclovine (18F)) in Poland

18, June, 2018

Blue Earth Diagnostics Announces Fluciclovine F 18 Research Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

21, May, 2018

Results from Blue Earth Diagnostics’ LOCATE Trial Show 59% of Patients with Suspected Recurrent Prostate Cancer Had Change in Management Plan Following 18F Fluciclovine PET/CT Scan

14, May, 2018

Blue Earth Diagnostics Announces Presentation on Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer at Upcoming AUA2018, Annual Meeting of the American Urological Association

02, May, 2018

Blue Earth Diagnostics Expands Oncology Portfolio with Exclusive, Worldwide Licensing of Investigational Radiohybrid PSMA-targeted Agents for Prostate Cancer from Scintomics

12, April, 2018

Blue Earth Diagnostics opens new headquarters in Oxford

20, February, 2018

Blue Earth Diagnostics Announces Addition of Axumin® (Fluciclovine F 18) to NCCN Guidelines® for PET Imaging for Suspected Recurrent Prostate Cancer

06, February, 2018

Blue Earth Diagnostics Announces Presentation at Upcoming ASCO 2018 Genitourinary Cancers Symposium on Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer

NEWS FROM 2017

10, October, 2017

Blue Earth Diagnostics and Seibersdorf Laboratories Announce Manufacturing and Distribution Agreements for Axumin® (fluciclovine (18F)) for PET Imaging of Recurrent Prostate Cancer

02, October, 2017

Blue Earth Diagnostics and GE Healthcare sign UK manufacturing agreement

06, September, 2017

Blue Earth Diagnostics Announces Late-Breaking Initial Results of Fluciclovine (18F) PET/CT Impact on Clinical Management of Recurrent Prostate Cancer at Upcoming ASTRO Annual Meeting

30, August, 2017

Blue Earth Diagnostics Named as Finalist in First Annual Xconomy Awards

11, August, 2017

Blue Earth Diagnostics shortlisted for “Best Emerging Medtech Company” award

27, July, 2017

Blue Earth Diagnostics appoints M2i to manufacture and distribute Axumin™ in Ireland

28, June, 2017

Blue Earth Diagnostics joins the British Institute of Radiology

23, May, 2017

Blue Earth Diagnostics receives marketing authorisation for Axumin™ (Fluciclovine (18F)) for PET imaging of recurrent prostate cancer

22, May, 2017

Advanced Accelerator Applications and Blue Earth Diagnostics Announce European Manufacturing and Distribution Agreements for Axumin™ (Fluciclovine (18F)) for PET Imaging of Recurrent Prostate Cancer

12, May, 2017

Blue Earth Diagnostics’ FALCON Trial of Fluciclovine (18F) PET/CT Imaging in Recurrent Prostate Cancer Stops Recruitment after Successful Interim Analysis

03, May, 2017

Blue Earth Diagnostics Announces Publication of Reader Training Study Results for AxuminTM (Fluciclovine F 18) PET Imaging of Men with Recurrent Prostate Cancer

24, March, 2017

Blue Earth Diagnostics receives positive CHMP opinion for Axumin™ (Fluciclovine (18F)) for PET imaging of recurrent prostate cancer

07, February, 2017

Blue Earth Diagnostics and Siemens’ PETNET Solutions Increase Patient Access to Axumin™ (Fluciclovine F 18) Injection PET Imaging Agent for Suspected Recurrent Prostate Cancer

NEWS FROM 2016

29, November, 2016

Blue Earth Diagnostics and Northern California PET Imaging Center Announce Region’s First Commercial AxuminTM (Fluciclovine F 18) Administration

25, October, 2016

The Journal of Urology Publishes Blue Earth Diagnostics’ Phase 3 Study Results of AxuminTM (Fluciclovine F 18) for PET Imaging of Recurrent Prostate Cancer

08, September, 2016

Blue Earth Diagnostics Announces First Commercial Administrations of AxuminTM (Fluciclovine F 18) by Atlanta’s Northside Hospital

08, September, 2016

Blue Earth Diagnostics Announces AxuminTM (Fluciclovine F 18) Presentations at Upcoming Scientific Conferences

10, June, 2016

Blue Earth Diagnostics and Siemens’ PETNET Solutions Announce Commercial Availability of AxuminTM (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer

09, June, 2016

Blue Earth Diagnostics Announces AxuminTM (Fluciclovine F 18) Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

03, June, 2016

FDA approves new diagnostic imaging agent to detect recurrent prostate cancer

03, June, 2016

U.S. FDA Approves Blue Earth Diagnostics’ AxuminTM (Fluciclovine F 18) Injection after Priority Review for PET Imaging of Recurrent Prostate Cancer

13, May, 2016

Blue Earth Diagnostics Announces Opening of U.S. Office and Expansion of Management Team

31, March, 2016

Blue Earth Diagnostics begins fluciclovine (18F) studies in Recurrent Prostate Cancer Patients

24, March, 2016

Blue Earth Diagnostics and Norsk medisinsk syklotronsenter AS announce manufacturing and distribution partnership for Fluciclovine (18F)

NEWS FROM 2015

02, December, 2015

Blue Earth Diagnostics and Siemens’ PETNET Solutions announce FDA acceptance of NDA filing for fluciclovine

23, July, 2015

Blue Earth Diagnostics receives £18M Series B Funding from Syncona Partners and establishes Blue Earth Diagnostics Inc

08, July, 2015

Blue Earth Diagnostics granted US and European orphan drug designation for fluciclovine (18F) in the diagnosis of glioma

21, May, 2015

Blue Earth Diagnostics signs an agreement with Siemens’ PETNET Solutions to manufacture and distribute prostate cancer PET imaging agent

NEWS FROM 2014

11, March, 2014

Syncona announces the formation of Blue Earth Diagnostics, a company developing PET agents for the detection of recurrent prostate cancer

NEWS FROM

19, October, 2021

Description event

European Conferences

European Conferences

U.S. Conferences

U.S. Conferences

Blue Earth Diagnostics is an established molecular imaging company on a growth trajectory to provide innovative, well differentiated diagnostics solutions, informing patients and driving future therapies in cancer. Formed in 2014, Blue Earth Diagnostics' success is driven by our management expertise and agility, supported by our demonstrated track record of rapid development and commercialisation of PET radiopharmaceuticals. Blue Earth Diagnostics’ clinical focus is exclusively in cancer.

READ MORE

Quick Links

Contact Information

The Oxford Science Park

Magdalen Centre,

Robert Robinson Avenue

Oxford OX4 4GA

© Blue Earth Diagnostics 2024. All Rights Reserved. Developed by RevM